News | May 11, 2026
Bajaj Healthcare FY26 revenue rises 12.6% to Rs 6,110 million
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
Enterprise-scale adoption in 2026 will be driven by domain-specific AI, compliance automation, and strong digital foundations across quality, manufacturing and regulatory workflows
SPARC enters definitive agreement to monetise rare paediatric disease PRV, unlocking capital for R&D and strategic growth
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
The collaboration will roll out an “agentic” AI platform across Merck’s research & development, manufacturing, commercial, and corporate operations
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
Subscribe To Our Newsletter & Stay Updated
